Education
About Us
Working with TipRanks
Follow Us
Geron Corporation (GERN)
:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $4.84
Previous CloseN/A
Volume1.63M
Average Volume (3M)9.57M
Market Cap
$764.30M
Enterprise Value$907.74M
Total Cash (Recent Filing)$396.88M
Total Debt (Recent Filing)$121.78M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 06, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding636,917,800
10 Day Avg. Volume11,367,357
30 Day Avg. Volume9,574,970
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)8.16
Price to Sales (P/S)29.70
P/FCF Ratio-10.43
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue7.81
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-7.57
Forecast
1Y Price Target
$3.50Price Target Upside191.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Product AwarenessThe continued medical conference presence may be helpful to further bolster physician awareness and education on Rytelo.
Sales Force ExpansionOptimism exists that a positive impact from the expanded sales force may be seen in the back half of the year.
Sales PerformanceThe key driver for the stock in the near to medium term is the Rytelo sales trajectory, which is starting to show a modest-but-positive trend.
Bears Say
Market ReactionManagement admitted the Rytelo launch had flat-lined, followed by a share price meltdown and CEO change.
Sales DeclineRytelo sales declined q/q and came in below expectations.
Sales ExpectationsRytelo will not reach current consensus expectations for peak sales, resulting in sustained pressure on stock performance over the intermediate-term.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.09 and its highest was $4.84 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $764.30M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Nov 06, 2025 which is in 91 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on Aug 06, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.029 by $0.009.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is -0.03.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 636,917,800 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.029. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (191.67% Upside)
$3.50 (191.67% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 25.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.39%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
16.67%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Company Deck
GERN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a mixed sentiment. While there are encouraging signs of growth and strategic investments to bolster RYTELO's market presence, the decline in Q1 revenues, challenges in physician adoption, and reliance on third-party support in the EU present significant concerns. The ongoing executive transition adds to the uncertainty.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$3.50
▲(191.67% Upside)
Technical Analysis
Ownership Overview
0.10% Insiders
12.67% Mutual Funds
0.09% Other Institutional Investors
72.64% Public Companies and
Individual Investors